Mesenchymal stem (stromal) cells (MSCs) are a source of circulating progenitors that are able to generate cells of all mesenchymal lineages and to cover cellular demands of injured tissues. The extent of their transdifferentiation plasticity remains controversial. Cells with MSC properties have been obtained from diverse tissues after purification and expansion in vitro. These cellular populations are heterogeneous and under certain conditions show pluripotent-like properties. MSCs present immunosuppressive and anti-inflammatory features and high migratory capacity toward inflamed or remodeling tissues. In this study we review available data regarding factors and signaling axes involved in the chemoattraction and engraftment of MSCs to an injured tissue or to a tissue undergoing active remodeling. Moreover, experimental evidence in support of uses of MSCs as vehicles of therapeutic genes is discussed. Because of its regenerative capacity and its particular immune properties, the liver is a good model to analyze the potential of MSCbased therapies. Finally, the potential application of MSCs and genetically modified MSCs in liver fibrosis and hepatocellular carcinoma (HCC) is proposed in view of available evidence.
Bone marrow-derived cells contribute to healing of distant tissues
More than 100 years before Friedenstein's observation regarding the broad differentiation potential of the adherent cellular fraction of the bone marrow, Julius Cohnheim 1 made a striking proposal; fibroblasts present in a tissue under repair were originated from bone marrow-derived circulating cells. 2 Thereafter, Cohnheim's findings lingered forgotten. Nevertheless, during the past 50 years, the concept of circulating progenitors appeared once and again. It came first from research groups pursuing other main line of investigations and whose observations about circulating stem or progenitor cells remained anecdotic; that is the case of the early independent studies of Stump and Gonzalez and their collaborators on arteriosclerosis, and the reported host origin of an arterial thickening from an allografted heart. [3] [4] [5] Yet, these early studies have been useful thereafter as a conceptual platform for other groups who started wondering whether only local cells could suffice the cell demands of an injured organ or whether the accepted understanding about local tissue cells deriving from resident stem cells was absolute.
It was not until the late 1990s that substantial evidence from different groups permitted the resurgence of Cohnheim's old idea: self-renewing cells from a distant site may contribute to the cellular pool of a tissue under active turnover, for instance, in tissue regeneration that occurs during wound healing. Thus, Asahara et al. 6 showed that a pool of CD34 + and FlK-1 + cells from the bone marrow were incorporated into ischemic tissues, and hence contributed to the development of the new vasculature. Almost simultaneously, Shi et al. 7 provided evidence for the existence of CD34 + bone marrowderived precursors that contributed to the endothelialization process.
MSCs: mesenchymal stem (or stromal) cells? How broad is their transdifferentiation plasticity?
The bone marrow is the main source of systemic circulating cells in the adult, most of them requiring a very high turnover. For this reason and because of its accessibility, populations of bone marrow stem/ progenitor cells are fairly well characterized. Both the hematopoietic stem cell (HSC) fraction of the bone marrow and the adherent, mesenchymal fraction have been identified as sources of circulating progenitors.
Cell populations obtained from the cultured adherent fraction of the bone marrow are called mesenchymal stem (or stromal) cells (MSCs) to highlight their longterm ability in culture to self-renew and to differentiate into cells of the mesenchymal progeny. 8, 9 In this context, the term 'mesenchymal' defines a progenitor cell with fusiform shape and able to actively move, or as opposed to 'epithelial' or 'parenchymal'. From the embryological point of view, 'mesenchymal' refers to the middle embryological germ layer (mesoderm) that gives rise to skeletal muscle cells, blood, vascular and urogenital systems and connective tissues throughout the body. [10] [11] [12] In this respect, the term mesenchymal is misleading as MSCs give rise to the connective compartment of tissues but not to blood, which is instead generated and maintained by HSCs. 12, 13 Nevertheless, an early developmental connection could be established when considering the hemangioblast as a precursor of both the blood and vascular compartments 12, 14 or the yet unconfirmed bone marrow primitive MSCs able to generate other MSCs as well as blood cells. 15 Given that they contribute to the supporting tissue of the bone marrow and other organs from where they were isolated, they are also referred to as mesenchymal stromal cells. 10, 16 Despite intense studies, it is still not possible to identify MSCs in vivo as no combination of markers and/or assays are suitable for that. 12 Therefore, their ability to adhere to plastic, their fibroblast-like morphology, their differentiation capacity toward chondrogenic, adipogenic and osteoblastic lineages and a combination of positive staining for fibroblast markers and negativity for hematopoietic markers such as CD45 and CD34 are all accepted hallmarks of MSCs. 17, 18 On the other hand, their capacity to transdifferentiate to myocytes, cardiomyocytes and neurons remains controversial. [19] [20] [21] [22] [23] [24] It could be anticipated that bone marrow-derived MSCs (BM-MSCs) would be able to differentiate in vitro toward the osteogenic, adipogenic and chondrogenic phenotypes, as marrow-containing bones undergo active remodeling within their trabecular array 10, 25 and adipose tissue is also present within the bone marrow. 10, 26 Similarly, the ability of MSCs to give rise to cartilage may be recognized in the process of bone fracture repair, in which the fracture site forms first a cartilage deposition that is subsequently replaced by bone. 10, 27 These events partially recapitulate the development of skeletal bones during embryonic stages; mesenchymal stem-like cells generate chondroblasts and chondrocytes that are able to build a transitional cartilaginous skeleton model that is later replaced by bone through chondrocyte calcification and osteogenesis. 27 Several recent articles have stressed the capacity of MSCs to differentiate into hepatocytes, based on specific markers and on the ability to produce albumin or to store glycogen. [28] [29] [30] Are MSCs isolated from different tissues similar?
After systematic approaches to isolate MSCs from different post-natal organs and tissues, research groups have described MSCs derived not only from bone marrow but also from adipose tissue, 31 synovial membrane, 32 synovium fluid, 33 tendon, 34 periodontal ligament, 35 lungs, 36 placenta, 37 umbilical cord blood, 38 umbilical cord, 39 scalp 40 and menstrual blood. 41 MSCs isolated from different sources might have originated from a primitive cell that is able to contribute to the connective tissue compartment. During post-natal life, these organ-specific MSCs could exert an effect as a reservoir to sustain tissue repair. Moreover, the differentiation capacity of MSCs from different sources points to a role of the microenvironment in biasing the fate of MSCs. MSCs isolated from this variety of tissues share the basic characteristics that define this heterogeneous cell population, although with differences. The site and conditions of extraction is reported to influence cell behavior; for instance, MSCs from alveolar bone show less chondrogenic and adipogenic potential compared with iliac crest bone. 42 Human cord blood-derived MSCs could eventually differentiate to cardiomyocites and hepatic cells. 43 Although still under controversy, a special MSC subpopulation behaves as multipotent stem cells after blastocyst injection and chimera mouse production. 44 Interestingly, genome-wide expression profiles of MSCs obtained from adipose tissue, cord blood and bone marrow showed significant differences. 45 In addition, diverse MSCs even though isolated from the same donor did not cluster together; nevertheless, 25 genes were expressed at similar levels in preparations of all MSCs, and this is what increases the robustness of the definition of MSCs despite their heterogeneity. 45 Furthermore, amniotic fluid-derived MSCs showed an important number of unique proteins when compared with BM-MSCs after proteomic characterization, suggesting that MSCs from different sources only partially share their characteristics. As different factors can influence MSC properties and capabilities to differentiate, 46 care must be taken when comparing biological responses of MSCs isolated from different sources or using different isolation methods. Far from being a hindrance for research purposes, one can interpret this heterogeneity as a biological measure of non-clonal derivation of subpopulations of MSCs in standard protocols. 18, 47 In this regard, MSCs plated on fibronectin-coated plates and incubated in embryonic stem cell culture medium express embryonic stem cell markers such as SSEA-1, Oct-4 and Nanog and present pluripotent-like properties, 15, 44, 48, 49 and because of their unique properties they were named as 'multipotent adult progenitor cells' and 'marrow isolated adult multilineage inducible stem cells'. It is noteworthy that multipotent adult progenitor cells present an expression profile that significantly differs from that of MSCs cultured on plastic regarding markers such as CD44 and H-2K (MHC I, RT1a). 44, 48, 50, 51 Changes in the expression levels of these two factors have potential implications in MSC adhesiveness or immunological properties and might be therefore relevant for cell therapy purposes.
Immunosuppressive features of MSCs
MSCs are regarded as non-immunogenic. The characterization of MSCs includes the expression of a combination of markers, and the absence of hematopoietic markers and co-stimulatory molecules. MSCs are depicted as HLA class I+, HLA class II-, CD40-, CD80-and CD86-. 52 In MSCs, interferon-g addition results in the upregulation of HLA class I and in the expression of HLA class II; nevertheless, this change in the immunophenotype MSCs as therapeutic tools and gene carriers JB Aquino et al does not result in any immunogenic response, as the absence of costimulatory molecules in MSCs cannot connect to a secondary signal and T cells remain anergic. 53 In addition, it was reported that activated T cells are suppressed when co-cultured with MSCs. 54 MSCs exert an inhibitory effect on activated effector cytotoxic T lymphocytes, which represent a cellular subset that mediates graft-versus-host disease. 55 The mechanisms by which MSCs can exert an effect as immunossuppressants are not clear, although some reports involve soluble factors released by MSCs, such as PGE 2 55 or cell-cell contact. 56 Ren et al. 57, 58 have recently shown that the immunosuppressive function of MSCs is likely induced by pro-inflammatory cytokines produced by T cells and that it may rely on nitric oxide (mouse) or human indoleamine 2,3-dioxygenase production from MSCs. This immunosuppresive nature of MSCs was found to influence other immune cells; for instance, MSCs can inhibit the differentiation of dendritic cells as well as B-cell proliferation, differentiation and chemotaxis. [59] [60] [61] [62] It is remarkable that the immunosuppressive properties of MSCs are maintained when they differentiate into osteoblasts, chondroblasts and adipocytes, 63 suggesting that if in situ tissue differentiation indeed takes place, the resulting differentiated cells may continue showing their inherent non-immunogenic features. MSCs are resistant to cell death, mediated by both cytotoxic T lymphocytes and natural killer cells. 63 In sight of the immunosuppressive properties of MSCs, they have been used to treat graft-versus-host disease (http://clinicaltrials.gov/ct2/show/NCT00603330; 64 ) and have been co-administered with HSCs in allogeneic transplants to improve engraftment (http://clinicaltrials. gov/ct2/show/NCT00823316). 65 Diseases with an inflammatory component and immune or even autoimmune features such as multiple sclerosis could benefit from the immunosuppressive properties of MSCs. Indeed, administration of MSCs improved symptoms of mice with experimental autoimmune encephalomyelitis, which is an experimental model of multiple sclerosis. 66 Interestingly, MSCs or their conditioned medium were able to suppress corneal inflammation through soluble factors such as interleukin (IL)-10, transforming growth factor (TGF)-b1, IL-6 and thrombospondin-1. 67 Thus, MSCs should be viewed as a cell reservoir pool to refill tissues with high cellular demands that might also counteract strong inflammatory responses, which could ultimately elicit severe immunological and even autoimmune conditions. In this way, MSCs would not only cover cellular demands of injured tissues but could also control an unrestrained inflammatory response.
Their potential use as therapeutic vehicles: biodistribution of MSCs
Bone marrow-derived stem cells have been shown to participate in the regeneration of different tissues and organs, such as bone, 68 skin, 69 liver, 70 kidney, 71 heart, 72 spinal cord 73 and muscle. 74 Moreover, murine MSCs could be found in the bone marrow, spleen, thymus, kidney, brain, liver, aorta, muscle, lungs and vena cava. 75 MSCs could be located in vessel walls at the capillary level, although this is still under controversy. 31, [76] [77] [78] [79] Systemic administration using a variety of delivery routes resulted in the broad biodistribution and specific targeting of MSCs that was dependent of the administration route. 9, [80] [81] [82] Incorporation of MSCs into an injured/remodeling target tissue has been reported to drive MSC differentiation, 83 fusion 84, 85 or the provision of a stromal support network. 86 In terms of tissue therapy perspectives, simple consideration of the role of MSCs as just providing stromal support in the target tissue undermines their relative importance. Although they rarely differentiate into tissue parenchyma, 50 MSCs homing into a tissue undergoing regeneration could contribute to the stromal mass and still exert an effect as paracrine effectors; in addition, they could be manipulated to carry therapeutic genes and thus make possible a targeted delivery of relevant therapeutic factors (see below).
After systemic administration into normal, noninjured animals, MSCs were found in the lungs, kidneys, spleen and long bones for as long as 48 h; 9 the use of a vasodilator significantly improved the location of infused MSCs into the marrow of long bones, presumably because in that case MSCs were not trapped into the lung microvasculature. In addition, the hypoxic microenvironment in the bone marrow could have been conducive to the overexpression of chemotactic factors and other molecules promoting recruitment of MSCs. 87, 88 Under this situation, MSCs home into the bone marrow and into injured areas instead of remaining in the circulation. Thus, regions that are able to support migration due to injury requirements may out-compete those that are unable to sustain homing for a prolonged period of time. In this regard, it was shown that intravenously injected MSCs have preference to home into unilaterally irradiated tumors when compared with contralateral non-irradiated ones. 89 Irradiation was found to upregulate the expression of TGF-b1, vascular endothelial growth factor and plateletderived growth factor-BB, as well as chemokines involved in the trafficking of immune cells and MSCs into inflammatory sites, such as CCL2 and CCR8. Thus, tissue damage and inflammation have a decisive influence in trafficking and homing of MSCs.
The inherent tropism of MSCs to injured tissues mimicked their capacity to target tumors. A tumor environment is characterized by the increased production of inflammatory mediators through tissue damage occurring in the stroma. 90, 91 Networks of chemokines ultimately regulate tumor cell movement, leukocyte infiltrate and angiogenesis. 92 Thus, inflammation might exert an effect as a key effector in the targeted migration of MSCs into tumors and other inflammation-related environments, and modulation of the immune system would likely result in changes in the migration and engraftment capacities of MSCs. Fernández et al. 93 reported the presence of MSCs in the peripheral blood of breast cancer patients that were subjected to growth factor bone marrow mobilization protocols. However, this event was found to be rare by Lazarus et al. 94 after having applied similar procedures. The extent of systemic MSC circulation remains controversial in humans. [95] [96] [97] [98] [99] [100] Nonetheless, there seems to be sufficient evidence suggesting that BM-MSCs may exert regulatory roles during tissue regeneration, being able to support the cellular demands of connective tissues throughout the body and/or of tissues under stress. 89, [101] [102] [103] [104] [105] In fact, they have a similar role in their natural environment in MSCs as therapeutic tools and gene carriers JB Aquino et al which the stromal fraction of the bone marrow regulates the physiology of the hematopoietic cells and also regenerates the connective tissue cells within this organ. 13 One of the molecules likely having a crucial role in MSC homing is hyaluronic acid, a carbohydrate molecule found associated with the extracellular matrix (ECM) in the connective tissue whose levels increase after tissue injury/inflammation 106 and in tissue regeneration. 107 High concentration of hyaluronic acid results in a highly hydrated ECM that favors diffusion of chemokines and growth factors as well as cell migration. 108 Thus, induction of hyaluronic acid synthesis seems to favor the creation of chemoattractant gradients and the attachment, migration and tissue incorporation of infused MSCs. CD44 is the principal cell surface receptor for hyaluronic acid 109 and is a marker of MSCs. Herrera et al. 51 reported that hyaluronic acid is able to stimulate migration of mouse MSCs (mMSCs) in a dose-dependent manner and that CD44 expression in MSCs is required for murine MSC engraftment into the epithelia of injured kidney in mice. Nevertheless, tissue-specific migration and engraftment of MSCs require additional adhesive and chemotactic factors. 110 One of the factors likely involved in the chemoattraction and/or tissue engraftment of MSCs is the chemokine, monocyte chemotactic protein-1. This chemokine was found to be secreted by breast tumor primary cultures and breast tumor explants and it was shown to promote recruitment of MSCs into the tumor 111 as well as to enhance their mobilization during experimental brain ischemia. 112 The elucidation of tissue-specific chemotactic axes and adhesion motives would permit the manipulation of MSCs to direct their trafficking toward specific organs for therapeutic purposes.
As previously mentioned, MSCs preferentially target tissues under remodeling, overexpressing chemotactic factors. For cell therapy purposes, a more specific targeting of MSCs to an injured or remodeled tissue is highly desired. As the alleged heterogeneity of the MSCs seems to be microenvironmentally dependent, 113 a robust environmental influence could be turned into a modulating tool to enhance specific targeting. As the first barrier that a migrating cell must overcome to reach an inflamed tissue is the vascular bed, 110, 114 specific MSC arresting to adhesion molecules expressed on endothelial cells from the injured tissue area could anchor MSCs for a period of time that would suffice for MSCs to respond to gradients of chemotactic and homing factors in the affected area.
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Combining cell and gene therapy Gene therapy is a promising novel therapeutic strategy for treatment of several heritable and non-heritable human diseases, including infections, degenerative disorders and cancer. 117, 118 The genetic material is packaged into vectors, which can be of viral and non-viral nature. Viruses are modified to eliminate their pathogenic properties and adapted to transport the desired therapeutic genetic material. 119 Viral-based vectors have several limitations when administered directly to the host; that is, they may generate innate and specific antiviral immune responses against viral proteins. As a consequence, the half-life of the vector is reduced and some non-desired side effects are usually manifested in the host when viral vectors are systemically applied. 120 The possibility of ex vivo manipulating cells using gene therapy strategies with the aim of further infusing them into the host has generated much attention. This approach, which combines both gene and cell therapy, could be a way of avoiding the immune-mediated elimination of the vector and might constitute an efficient system for organ/tissue-specific long-term delivery of factors without inducing undesired effects in the host.
The potential use of MSCs for therapeutic-gene delivery was suggested by Matthews and Keating 121 and Allay et al. 122 Initial experiments on virus-mediated transgene expression in MSCs showed efficient cell transduction with retroviral vectors expressing lacZ or IL-3 genes, and no changes in differentiation potential of MSCs after gene transfer. 122 Thereafter, different groups were able to detect systemic levels of human growth hormone or IL-3, produced by either canine or murine transduced MSCs, up to several months after infusion. 123 
MSCs as vehicles of therapeutic genes and viruses in cancer treatment
The development of strategies to impair tumor growth has been historically directed to eliminate tumor parenchymal cells. For example, studies showed that naive MSCs co-administered intravenously with human Kaposi's sarcoma cells were able to reduce 50% of tumor size. 124 Studeny et al. 125 used human MSCs (hMSCs) producing interferon-b as 'Trojan horse' to inhibit the in vivo growth of established human melanoma xenografts implanted in nude mice. Interestingly, subcutaneously or intravenously injected MSCs were specifically recruited to melanoma tumors and such microenvironment induced proliferation of MSCs. 125 Remarkably, MSCs injected intratumoraly or into the contralateral hemisphere in a rat glioma model, 126 or hMSCs delivered through the carotid artery in a mouse intracranial glioma model 127 were able to specifically home into the tumor site, showing that MSCs possess tumor specificity and the ability to cross the brain blood barrier. Although naive MSCs were able to decrease tumor growth, enhanced antitumor effect was observed when cells were engineered to express IL-2. A preferential migration toward tumors for hMSCs was shown when they were intraperitoneally (i.p.) delivered in a human ovarian xenograft intraperitoneal model. 128 For cancer therapy, a more challenging ability for MSCs is to reach a metastatic site. Studeny et al. 86 showed that intravenously delivered hMSCs homed into breast and melanoma lung metastases in a xenograft mouse model. 129 A prolonged mouse survival was observed when MSCs transduced with an adenoviral vector expressing interferon-b were administered systemically. 86 The researchers showed specific tumor site homing, disregarding a nonspecific trapping effect due to the lung microvasculature. Nodal metastatic breast tumors (MDA-MB-231 derived) were also shown to recruit systemically delivered naive MSCs. 111 The importance of the stroma for tumor development has led to the design of therapeutic strategies aimed at targeting several cell types of the tumoral stroma, such as monoclonal antibodies devised to block the growth of MSCs as therapeutic tools and gene carriers JB Aquino et al new blood vessels. 130, 131 However, a malformed vasculature and increased interstitial fluid pressure, characteristics of malignant tumors, hamper antibodies efficiencies. 132 These barriers also affect the therapeutic efficacy of viral or non-viral vectors, [133] [134] [135] although recent data from our group have shown that targeting stromal cells with a conditionally replicative adenoviral vector improved viral therapeutic efficacy. 136 As the tumor stroma is highly permissive for cell migration, 137 a cell therapy strategy using MSCs as vehicles for gene delivery is expected to overcome the problems related to tumor penetrability.
MSCs as vehicles of oncolytic viruses
Replication-competent recombinant oncolytic viruses, such as conditionally replicative adenoviruses, have received much attention during the past years because of their potential to treat human cancer diseases. 138, 139 Although there is a large experience in the clinical application of this type of vectors, their efficacy in terms of objective responses is very limited and further improvements are required for this treatment to be therapeutically significant. 140 The main challenges that this promising strategy has to face are: (1) specific targeting of oncolytic viruses to tumors and the ability to evade the anti-viral immune response and (2) the reduced capacity of oncolytic viruses to extravasate from tumor blood vessels and to reach and transduce cancer cells. Therefore, strategies to improve the delivery of oncolytic viruses are urgently needed. One of the explored tools is the use of cells as vehicles to deliver oncolytic viruses and to facilitate the access to tumors of virus-infected carrier cells. 129 These carrier cells can be of different origins, such as cancer cells, dendritic cells, lymphocytes or stem cells (MSCs, endothelial progenitor cells or HSCs). 118 Carrier cells can exert an effect as protectors for the therapeutic vectors that they contain and as factories to facilitate viral replication.
MSCs have been shown to migrate to tumors after systemic administration in response to hypoxia stimuli generated by them. On the basis of that and on the known ability of oncolytic vectors to efficiently infect MSCs, these cells seem to be good candidates as carriers for oncolytic-based gene therapy. 128, 141 Encouraging results have been achieved using this approach for oncolytic adenovirus transfer in the experimental treatment of ovarian carcinoma. 128 In this study, it has been shown that bone-marrow derived hMSCs home to ovarian tumors in vivo and that an enough amount of vectors is released by them to facilitate their replication and to inhibit tumor growth. 128 Moreover, Stoff-Khalili et al. 129 showed that systemic application of hMSCs transduced with conditionally replicating adenoviruses was able to suppress the growth of breast carcinoma pulmonary metastasis.
MSCs as vehicles of therapeutic genes in non-cancerous disease
Other kind of diseases could also be benefited by the use of genetically modified MSCs. For instance, in a rat model of cardiac ischemia, cell death of transplanted MSCs was significantly reduced when cells were engineered to produce Akt1 (the gene encoding for the Akt pro-survival protein). 142, 143 Consequently, a full recovery in cardiac function and an almost complete rescue of myocardial volume were observed. Application of hMSCs modified to express human insulin by a retroviral vector was able to ameliorate diabetes in rats. 144 Later on, the same group showed reversion of hyperglycemia after administration of insulin-expressing mMSCs into the liver. 145 Overexpression of RANK-Fc in mMSCs was found to increase bone mineral density in ovariectomized mice. 146 Moreover, Horwitz et al. 147 showed that children with Osteogenesis Imperfecta, a genetic disease characterized by production of defective type I collagen, improved their bone histology and clinical outcome after un-manipulated administration of bone marrow cells. Thereafter, the same group showed that when BM-MSCs were administered into children with Osteogenesis Imperfecta, their clinical outcome was improved. 148 In another study, MSCs from an Osteogenesis Imperfecta patient were manipulated to express collagen 1 and they were found to differentiate in vitro into mineralizing cells. Further studies are needed to show the efficacy of manipulated MSCs over preparations of naive MSCs that were used in the past. 149 Overall, the significant improvements reported regarding experimental applications of gene-modified MSCs in different disease models raised expectations for their future potential application in the clinics.
Are MSCs potentially tumorigenic?
Despite the potential use of MSCs as a therapeutic tool for gene delivery, several reports raised the concern of their intrinsic tumorigenicity. For instance, evidence was presented that human MSCs are the progenitors of malignant fibrous histiocytoma through a mechanism that involves inactivation of the Wnt pathway. 150 Moreover, the in silico gene expression analysis of Ewing tumors strongly suggests that MSCs could be the cellular origin of these tumors, and this might explain their high incidence in bones and soft tissues, 151 although a putative neural crest origin cannot be ruled out. 152 A striking report by Houghton et al. 153 raised the intriguing possibility that bone marrow-derived cells recruited to the stomach after infection with Helicobacter were the source of gastric cancer. In addition, MSCs exposed to conditioned media obtained from breast cancer cells might show properties of carcinoma-associated fibroblasts. 154 Thus, the evidence suggests that human MSCs can indeed turn tumorigenic in vivo, despite the fact that they do not seem to undergo transformation after long-term in vitro culture. 155 In this regard, it has been recently shown that 40 to 50% of hMSC cultures could undergo in vitro transformation and might become tumorigenic in vivo.
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This feature is most probably related to a long culture time exposure, and also not to a particular attribute to MSCs but to any cell type undergoing extensive ex vivo culture. With this scenario it would be necessary to reassure that ex vivo engineered MSCs administered for therapeutic purposes could be eliminated after having accomplished their goals. The 'suicide' Herpes Simplex virus thymidine kinase 157, 158 or the bacterial cytosine deaminase genes 159 are few of the examples of genes that can be used as a 'double locked' system to avoid untoward effects of administered MSCs. On the other hand, the potential tumorigenicity of MSCs or their capacity to generate an immunosuppressive ambience could be abolished for instance by the toxic effect that the oncolytic viruses might exert over their own MSC carriers. Alternatively, recent studies suggested that antiangiogenic effects were only achieved when a large number of MSCs was inoculated into tumors, whereas a low number of MSCs would eventually contribute to the tumorigenic process. It was proposed that tumors evolve in a way that they could recruit a comparatively low number of MSCs that directly contribute to tumor growth and metastasis. 160, 161 Connected to this, genetic manipulation of MSCs to enhance their tropism toward a tumor would increase recruitment of MSCs after systemic administration and might result in antitumoral responses.
Liver regeneration: a good reason for choosing liver models in experimental MSC-based therapies
Since a long time it is well known that liver has a remarkable capacity to regenerate after injury (see reviews in references 162, 163 ). Liver regeneration occurs in all mammals after a major loss of hepatic tissues, which are able to survive a 75% liver mass loss. 164, 165 Hepatectomy of different degree is the most frequently used model to analyze this process. 166 After partial hepatectomy, many cellular populations, mainly hepatocytes, and also biliary epithelial cells, Kupffer cells, endothelial cells and stellate cells, rapidly respond in an organized way to make possible a full liver mass recovery. 163 At least in case of severe liver injury or deficient hepatocyte response, the liver oval cells are also implicated 164, 167, 168 as well as some stellate cells, likely those expressing CD133, 169, 170 as a reservoir of hepatocyte progenitors. A contribution from bone marrow or other extrahepatic stem/progenitors cells to liver regeneration might also be relevant in such circumstances. 164, [171] [172] [173] [174] [175] The hepatocytes have a major role in liver regeneration: approximately 90% of these cells enter the S phase in waves, starting from periportal areas (close to parenchymal afferent vessels) and progressing toward pericentral regions (close to efferent veins), in a timeframe of 24-48 h. 176 In addition, hepatocytes produce and release many cytokines and growth factors exerting autocrine and paracrine effects, which are also able to trigger the proliferation of adjacent cells. Concomitantly, non-hepatic cells were found to secrete molecules enhancing the mitogenic response of hepatocytes, setting up a positive proliferation feedback loop. From these factors, interleukin-6 released by Kupffer cells is an important factor sensitizing hepatocytes to mitogenic growth factors and being able to trigger biliary epithelial cell proliferation. 177, 178 A parallel event to liver cells proliferation is the appearance of tissue remodeling signals. For instance, several ECM proteins and metalloproteinases are induced after hepatectomy, in spatialtemporal pattern resembling that of hepatocyte proliferation events. 179, 180 The repertoire of growth factors and cytokines involved in liver regeneration is complex and includes: bone morphogenetic protein-7, epithelial growth factors, hepatocyte growth factor (HGF), insulin-like growth factor-1, vascular endothelial growth factor, tumor necrosis factor and urokinase. 162, 163, 181, 182 Signaling events driven by these molecules were found to be largely redundant, ensuring the efficiency of the liver regeneration process. 163 In addition, survivin, a protein involved in negative regulation of program cell death, has recently been shown to be upregulated during liver regeneration and to mediate hepatocyte proliferation. 183 Finally, TGF-b1, another cytokine found upregulated after partial hepatectomy, has a central role in liver tissue remodeling events. Interestingly, TGF-b1 is involved in liver regeneration termination after liver mass recovery, 162 although its effect might be partly indirect and depend on induction of stellate cell activation and enhanced ECM synthesis (see behind). In fact, ECM has been shown to negatively regulate liver regeneration through integrin signaling events. 184 The remarkable tissue remodeling and regenerative properties of the liver make it a very interesting target for experimental MSC therapy, as any relevant positive effect of these cells on disease models would likely be more evident when applied to this organ. In addition, MSCs were shown to produce and release factors directly involved in liver regeneration, such as HGF, tumor necrosis factor and IL-6
185-188 and they were found to sustain hepatocyte survival and differentiation in coculture systems. 186 For the previous reasons, in the next part of this review we will focus our attention on discussing the literature available on the effects of application of MSCs in liver fibrosis and hepatocellular carcinoma (HCC) models.
A role for MSCs and engineered MSCs in the treatment of liver fibrosis: factors involved in MSC migration/engraftment
Cirrhosis, the most advanced stage of liver fibrosis, also involves liver regeneration and it is characterized by an excessive accumulation of ECM followed by the appearance of hepatocyte regenerative nodules that distort liver morphology. [189] [190] [191] As a consequence, there is an increased intrahepatic resistance to blood flow resulting in portal hypertension and liver failure. The hepatic stellate cells (HeSCs), also known as Ito cells, have a key role in liver fibrogenesis. 192 These cells, which are of possible hematopoietic stem cell origin, 193, 194 are located close to sinusoids and extend projections surrounding hepatocytes in the Disse space. Under physiological conditions, HeSCs remain quiescent. After chronic injury of any etiology, HeSCs become activated, enter cell cycle and differentiate into myofibroblasts, which start producing collagen and other ECM proteins 195 as well as growth factors, cytokines and chemokines with mitogenic activity. 192 It has been shown 196 that in vivo and in vitro activated HeSCs express higher levels of fibrogenic factors, such as TGF-b1 197 and endothelin-1, 198 as well as other factors such as fibroblast growth factor-7, frizzled-2, insulin growth factor-1 and vascular endothelial growth factor. Others have reported upregulation of epidermal growth factor and HGF expression in HeSCs through progression of liver fibrogenesis. 199 Many of [200] [201] [202] and might be involved in their migration toward the fibrotic liver (see Figure 1) .
Engraftment of MSCs within areas of active fibrogenesis might involve positive sensitization priming of SDF1-CXCR4 axis through hyaluronic acid/urokinasetype plasminogen activator receptor/fibronectin among other signals. 203 Several studies have shown upregulation of stromal cell-derived factor-1a (SDF1-a) during liver fibrogenesis. [204] [205] [206] Interestingly, HGF plasma levels were found to be increased in cirrhotic patients and they were even further increased under conditions stimulating bone marrow stem cell mobilization, such as granulocyte colony-stimulating factor application, what may contribute to chemoattract bone marrow-derived stem cells toward the damaged liver. 97, 207 MatsudaHashii et al. 208 showed that HGF neutralization inhibits production of IL-11, SDF-1 and stem cell factor (also known as steel factor or c-kit ligand) by hMSCs and reduces their proliferative and adhesive capability. Consistently, Asano et al. 209 reported upregulation of SDF1-a expression by HGF gene transfer within the fibrotic liver parenchyma. Thus, HGF could be considered as a master molecule for MSC recruitment as it induces the expression of SDF1-a, another hMSC chemoattractant. In addition, it was recently reported that Toll-like receptors, which are involved in the detection of microbial infections, in immune responses and in noninfectious inflammation, 210, 211 have chemoattractant properties on hMSCs. 212 Thus, several molecules are likely implicated in MSC migration and engraftment into a tissue suffering from active inflammation and/or fibrogenesis. Some of the implicated chemotactic axes are pleiotropic, such as CXCR4-SDF1, and tissue specificity for MSC homing would therefore likely be provided by the damaged organ-specific growth factors. Our increasing knowledge on the migration ability of MSCs and the mechanisms and signals involved in their recruitment and incorporation to a given organ would likely help in developing new strategies aimed at increasing MSC retargeting, which appears as the 'bottle neck' for the efficient use of MSC in some experimental cancer models and in the clinics. 213 
MSC contribution to liver fibrogenic process
MSCs are recruited to the injured liver of patients as well as in animal models contributing to the fibrogenic process. 193, 214, 215 SPARC (secreted protein acidic and rich in cysteine) is a matricellular glycoprotein involved in many biological processes, including cell adhesion, proliferation, wound healing and migration, 216 and was found to be overexpressed in cirrhotic livers of both animal models and patients. 217, 218 SPARC was shown to be specifically expressed in HeSCs and its downregulation was found to ameliorate the degree of fibrosis in an animal model established in rats chronically intoxicated with thioacetamide. 219 Interestingly, MSCs were reported to express significant levels of SPARC, 220, 221 which suggests that while they are undifferentiated they might contribute to the fibrogenic process.
Different MSC subpopulations might have diverse multipotent and/or plastic properties and thus environmental factors might eventually determine or change their differentiation status. TGF-b and platelet-derived growth factor are known to be highly expressed by fibrotic liver 189, 222, 223 and to induce myofibroblast differentiation in MSCs. 47 Human MSCs were shown to have the ability to respond to TGF-b 224 and were found to proliferate in the presence of this growth factor. 225 In addition, platelet-derived growth factor was shown to exert an effect as MSC chemoattractant. 127, 201, 202 As expected, di Bonzo et al. 50 and Li et al. 226 have recently shown that many MSCs recruited to the fibrotic liver become indeed myofibroblasts.
MSCs and their anti-fibrotic potential
Interestingly, and contrarily to what could be expected, systemic MSC application showed anti-fibrotic effects (Table 1) . Thus, Abdel Aziz et al. 227 reported that systemic infusion of syngeneic passaged 1 MSCs into rats with early fibrosis stages resulted in improved liver function and reduced degree of fibrosis. Zhao et al. 228 infused highly passaged (P8-P10) syngeneic MSCs into rats chronically injured with carbon tetrachloride (CCl 4 ) or with dimethylnitrosamine and obtained similar results. In addition, in the second model, which induces a more severe liver dysfunction, infusion of MSCs resulted in increased animal survival. Oyagi et al. 231 delivered primary-cultured plastic-adherent bone marrow cells to rats before CCl 4 administration and also reported antifibrotic effects. Interestingly, these researchers showed that pre-differentiation of these cells into hepatocytes, by incubation in the presence of HGF, Figure 1 Signaling factors likely involved in chemoattraction and engraftment of MSCs to the injured/remodeled liver. Activated hepatic stellate cells (aHeSCs) have recently being shown to secrete many factors that were reported by others to attract MSCs. In addition, they also secrete extracellular matrix proteins and glycose-amino-glycans, such as hyaluronic acid (HA), which may favor the creation of chemotactic gradients. MSCs were reported to express the receptors required for such signals to induce intracellular mechanisms that drive subsequent changes in cellular behavior. In green: factors produced by aHeSCs. In black: factors upregulated in the fibrotic liver with unknown cellular origin. reported better liver functional recovery when clonally derived, negatively selected mMSCs were delivered at the onset of CCl 4 injury but not when they were applied 1 week after damage initiation. Kuo et al., 230 in a very detailed study, found that infusion of hMSCs in NOD-SCID mice treated with lethal doses of CCl 4 significantly increased survival rate. Using the same model, they also showed that application of hepatocyte-like cells, generated from hMSCs, resulted in improved survival when compared with nontransplanted animals, but this effect was less significant than that of naive hMSCs. Improvements in liver function found in the previously mentioned studies seem not to be mainly mediated by parenchymal cell replacement, but by paracrine mechanisms promoting survival of endogenous hepatocytes and proliferation of hepatocyte progenitors. 188, 230 MSCs could therefore exert their effects through secretion of cytokines 123, 232 and growth factors, such as HGF 185 or nerve growth factor. 233 While the former can trigger hepatocyte anti-apoptotic mechanisms, 234 or inhibition of fibrogenesis by exportation of Smad3, 235 the latter might result in HeSC programmed cell death. 236 In addition, MSCs were shown to inhibit HeSC activation and growth 187, 228, 237 and to present fibrinolytic capacity. 238 Moreover, MSCs are able to modulate HeSC immune function and to induce HeSC apoptosis, which likely also contribute to their anti-fibrotic effects. 187, 239 In di Bonzo et al., 50 although a significant proportion of MSCs were found to generate myofibroblasts, similar amounts of unidentified cells with low nuclear/cytoplasmic ratio were also reported, suggesting that they are likely refractable to myofibroblast differentiation under a pro-fibrogenic microenvironment. The latter population might be responsible for the beneficial effects usually retrieved when applying MSCs. It is remarkable that: (1) specific markers to isolate MSCs are still elusive; (2) MSC cultures are highly heterogeneous regarding several markers 240 ; and (3) only half of MSC cultures were found to undergo transformation. All of these issues, among others, seem to suggest that the apparent discrepancies between the pro-fibrogenic capacity of MSCs and the anti-fibrogenic properties reported from functional studies, even in the absence of therapeutic genes, might likely be explained by the coexistence of different populations in MSC samples. On the other hand, the different degrees of fibrosis generated in mice could influence the behavior of injected MSCs favoring pro-or anti-fibrogenic effects. Finally, the markers nowadays accepted as hallmarks to identify MSCs may be the result of in vitro selective forces but they may likely mask the large heterogeneity, regarding cell origin, phenotype and diferentiation potential, of MSC cultures.
MSC signaling mechanisms in liver fibrosis
As HeSCs are those principally involved in liver fibrogenesis, interaction between HeSCs and MSCs recently became a subject of investigation. Lin et al. 241 have recently reported functional sonic hedgehog Abbreviations: a, adipocyte cells; ALB, serum albumine; ALT, serum alanine aminotransferase aspartate; CCl 4 , carbon tetrachloride; ch, chondrocytes; DMN, dimethylnitrosamine; h, hepatocyte-like cells; HA, serum hyaluronic acid; hyp, hydroxyproline; i.p., intraperitoneal injection; i.v., intravenous injection; LD, clones obtained by limiting dilution; LN, serum laminin; MT, Masson trichrome; n, neural-like cells; ND, non-defined; NS, isolated by negative selection; o, osteoblasts; P-III-P, serum procollagen III-N-peptide; s.c., subcutaneous injection; TBIL, serum total bilirubin.
MSCs as therapeutic tools and gene carriers JB Aquino et al (Shh) signaling in both cell types and its effect on the proliferation and survival of MSCs. Although the quiescent/activated state of HeSC within transwell inserts was not analyzed and efficient levels of Shh in co-culture settings might be controversial, the researchers provided evidence suggesting an effect of Shh signaling in proliferation of MSCs but not in HeSCs. In addition, HeSC-derived Shh likely improves survival and hepatocyte differentiation of hMSCs. It is worth noting that the effects of Shh signaling events in models of liver fibrogenesis remain to be elucidated.
Deng et al. 242 have analyzed the effect of co-culturing Kupffer cells and activated HeSCs with MSCs. They found that activated HeSCs in the presence of Kupffer cells express significant levels of HGF and induce differentiation of MSCs into hepatocyte-like cells that are able to produce glycogen deposition. However, in their in vitro model, there is no direct cell-cell or cell-ECM contact in between different cell types, which may explain why hepatocyte differentiation is not that significant in vivo. 50, 243 For example, the ECM protein, osteopontin, was recently found to be required for myofibroblast differentiation.
244 CD44 and osteopontin interaction 245 might be relevant for MSC migration, engraftment and/or myofibroblast differentiation in the injured liver. 51, 246 Genetically engineered MSCs in the treatment of liver fibrosis Although at least some MSCs likely contribute to wound-healing mechanisms and fibrogenesis after liver parenchymal cell death, genetic manipulation of MSCs to locally produce therapeutic genes might result in alternative cell fates. Reports are just appearing suggesting a further significant liver function recovery after application of genetically engineered bone marrowadherent stem cells when compared with naive ones (Table 2) . Sun et al. 247 systemically infused to CCl 4 -treated animals, syngeneic, bone marrow-derived hepatocyte stem cells (BDHSCs), a type of MSC expressing few liver markers that were isolated from the bone marrow of bile ductligated rats. 248 Non-transduced cells were able to rescue liver function, whereas further improvement in disease outcome was obtained with cells transduced with an adenovirus expressing urokinase-type plasminogen activator. Local expression of urokinase-type plasminogen activator was shown to further promote prevention of HSC activation, reduction of TGF-b1 and of collagen I/III expression levels, upregulation of metalloproteinases and HGF expression levels and increased proliferation of liver parenchymal cells. Using similar kind of cells genetically modified to produce IL-10, Lan et al. 249 were able to suppress both inflammation and fibrosis in rats. In this study, infusion of IL-10 BDHSCs was found to induce HGF mRNA expression and proliferation of liver cells, resulting in normalization of liver function. Unfortunately, cell engraftment and phenotypic differentiation has not been sufficiently addressed in these studies.
Genetically engineered MSCs in the treatment of HCC
HCC is the sixth most common cancer and the third leading cause of cancer-related death worldwide ( Table 2) . 252 HCC accounts for 490% of primary liver malignancies and takes place mainly in patients with cirrhosis. 253, 254 Current therapeutic options are extremely disappointing and o30% of the patients can receive a curative therapy, consisting of resection, transplantation or loco-regional ablation. 254 Thus, in the majority of advanced HCC cases, curative treatments are not possible and the prognosis is dismal because of underlying cirrhosis as well as poor tumor response to standard chemotherapy. 118 For patients with advanced disease, representing the majority of patients at diagnosis, the only option includes sorafenib (Nexavar), an oral multi-kinase inhibitor, which increases survival in patients with HCC in approximately 3 months. 255 New therapeutic options are thus urgently needed for advanced or metastatic HCC.
Scientific evidences regarding therapeutic use of MSCs in HCC are scarce. It has been recently shown that hMSCs co-cultured with human HCC cells diminished their tumorigenicity in SCID mice. 250 These MSCs were also found to decrease proliferation and to induce apoptosis of HCC cells in vitro, with the potential involvement of Wnt signaling mechanisms. 250 Chen et al. 251 showed that BM-MSCs engineered to secrete IL-12 were effective in the prevention of HCC establishment in mice. Using this protective strategy, the researchers were able to achieve prolonged IL-12 expression without the toxicity associated with systemic levels of the cytokine. Moreover, systemic application of IL-12-secreting MSCs in pre-established HCC delayed metastatic progression. 251 Future perspectives in the use of engineered MSCs for liver fibrosis treatment There are no current efficient treatments for cirrhosis than liver transplantation. 189, 256 Importantly, one of the most frequent complications of cirrhosis is the development of HCC. 256 The therapeutic advantages of MSCs are many and significant: their immunosuppressive and anti-inflammatory properties, and their high migratory capacity toward inflamed sites 257 as a consequence of tissue damage or remodeling. Their source of origin is advantageous; from decades, the bone marrow has been a source of HSCs for bone marrow transplants and it is an accessible organ when compared with other sources of adult stem cells such as neural stem cells. Moreover, research is now being conducted on adipose tissuederived MSCs, which is also an easily accessible source of cells. 258 Gaps in our understanding of the optimum time to infuse MSCs have to be filled. As the frequency of MSCs in a tissue such as bone marrow is low (0.01-0.001%), there is a need for ex vivo expansion before infusion into the host. Knowledge of factors involved in natural tropism of MSCs toward chronically injured liver or tumors and their tissue homing will improve liver cell-based therapy. It is important to determine the number of passages that MSCs can stand without losing their multipotent capacity and their ability to respond to chemoattractant signals derived from tumors and other injured tissues. 259, 260 Moreover, it is tempting to identify subpopulations of MSCs that could be more suitable for their application in different disease settings; some clues are provided in the work of Lee et al. 261 From syngeneic passaged 2 hMSC cultures, the researchers isolated a subpopulation of small, rapidly self-renewing MSCs MSCs as therapeutic tools and gene carriers JB Aquino et al with higher engraftment capacity than the larger, slowly renewing ones. Both subpopulations were found to have different gene expression patterns. 262 Interestingly, the self-renewing MSCs express significantly higher levels of chemokine receptors CXCR4 and CX3CR1, and their migration capacity was shown to be blocked by their specific neutralizing antibodies. Thus, it remains to be addressed whether a selection of mesenchymal subpopulations with higher capacity to migrate into an ischemic tissue and/or to promote angiogenesis and/or to reduce parenchyma cell loss, or those able to show an enhanced migration and homing to a tumor stroma, would result in therapeutic improvement. Characterizing the potential and plasticity of different subpopulations of mesenchymal stromal cell cultures will help to better understand the mechanisms of MSC mobilization/ recruitment and engraftment. Cell therapies based on utilization of engineered MSCs might constitute excellent vehicles for local release of factors modulating liver fibrogenesis 125, 126, [263] [264] [265] [266] or tumor growth. Further research on MSC biology could be instrumental in developing therapeutic tools for the treatment of liver cirrhosis, 29 eliminating at the same time the preneoplastic disease, and of HCC itself.
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